Sign In
Buy BRTX
$0.339
-0.0150 (-4.23%)
At Close: Jun 03, 2026
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
08:50am, Tuesday, 04'th Jun 2024
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapi
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
07:45pm, Friday, 24'th May 2024
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
09:00am, Wednesday, 15'th May 2024
MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
07:08pm, Tuesday, 14'th May 2024
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief
BioRestorative Therapies Provides First Quarter 2024 Business Update
04:10pm, Tuesday, 14'th May 2024
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-b
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
07:30am, Wednesday, 08'th May 2024
— New therapeutic candidate developed using Company's patented ThermoStem ® platform —
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04:15pm, Tuesday, 30'th Apr 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform —
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
07:45am, Tuesday, 16'th Apr 2024
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity —
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
07:45am, Monday, 01'st Apr 2024
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
04:15pm, Monday, 11'th Mar 2024
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based ther
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
09:15am, Wednesday, 14'th Feb 2024
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,
